Dear Editor, With increasingly successful treatment of malignancies, therapy-related leukemia (TRL) and myelodysplastic syndrome (MDS) are increasingly observed, especially in association with prior radiotherapy and the use of alkylating agents or topoisomerase-II inhibitors [1, 2] . They are characterized by lesions of chromosomes 5 and 7 and poor survival (median 7-10 months) [3, 4] . Azacitidine may be a reasonable treatment choice [5] although safety concerns in patients with complex cytogenetics [6] or previous acute promyelocytic leukemia (APL) exist [7] . Here, we present a case of two consecutive, individually rare TRLs following initial solid tumor and subsequent treatments with the development of unique translocation (13;17)(q12;q25). Azacitidine was successfully used achieving 1-year-long remission when patient relapsed, revealing a distinctive karyotype (Fig. 1) .
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A female patient aged 61 was diagnosed with breast cancer in 2006. She had mastectomy, received four cycles of doxorubicin/cyclophosphamide, four cycles of paclitaxel, and radiotherapy accomplishing remission.
In 2009, APL was diagnosed, PML/RARα positive (47, XX,+8,t(15;17)(q24;q21) [10] ). Antracycline/ATRA-based induction and three consolidation therapies were followed by 2-year ATRA/6-MP/methotrexate maintenance. Remission was soon achieved, and patient remained without detectable PML/ RARα transcript thereafter.
In 2013, the patient developed anemia requiring transfusion support. MDS (18 % blasts) with complex cytogenetics (45,XX,del(5)(q22q33),-7,t(13;17)(q12;q25), del(12)(p13),add(20)(q11)[cp15]) was diagnosed. Azacitidine was instituted as salvage therapy, and the patient became transfusion independent, achieving hematological remission. After 11 cycles, azacitidine had to be stopped due to the development of anemia and thrombocytopenia. Repeated revisions showed increased number of blasts (15 % progressing to 72 %) and alt e r e d c y t o g e n e t i c s ( 4 5 , X X , d e l ( 5 ) ( q 2 2 q 3 3 ) , -7 , t(13;17)(q12;q25),del(12)(p13) [20] ). Fluorescence in situ hybridization (FISH) was performed on the actual sample and retrospectively (at the time of MDS diagnosis) revealing 12p13 deletion was initially present in a subclone comprising 35 % of cells and now prevailing in 90 % of cells. 17p13 deletion was absent in both samples. The patient receives supportive treatment and remains alive more than 18 months since diagnosis.
Several interesting observations emerge from our case. Treatment-related malignancies represent a lifelong problem reflecting underlying genome instability (obvious weak point at chromosome 17). Unique translocation (13;17)(q12;q25) has not been described in MDS before and bears unknown prognostic significance (ZNF198, FLT3, BRCA2, and Septin from the rearranged chromosomal regions are possible candidate genes). Our heavily pretreated patient was successfully treated with azacitidine achieving prolonged remission. Therapy was well tolerated, and no reactivation of previous APL was observed [7] . However, disease control was ultimately lost with the expansion of clone harboring deletion 12p13 (locus of TEL/EFV6 gene) rendering azacitidine therapy ineffective. This association has not been described so far and implies potential molecular mechanisms worth investigating in further studies. No deletion of 17p13 (locus of TP53 gene) was detected, as assessed by FISH. Lesions of TP53 [8] and overlapping categories of monosomal and complex karyotype [4, 9, 10] are associated with inferior clinical outcomes in MDS patients treated with hypomethylating agents. MDS with complex cytogenetics may also represent an entity of higher risk for treatment [6] as resulting genome instability and selective action of hypomethylating agents on different subpopulations may favor the expansion of the most resilient clone (accelerating transformation to acute leukemia). This puts treating physicians Bbetween Scylla and Charybdisl eaving them to choose between Bless of two evils.^In our opinion, due to the lack of alternative treatment options in this especially unfavorable group of patients, azacitidine is still a reasonable choice.
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